ETMR-22. TITLE: DEFINING THE CLINICAL AND PROGNOSTIC LANDSCAPE OF EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (etmrs), A RARE BRAIN TUMOR REGISTRY (RBTC) STUDY
Sara Khan,Palma Solano-Paez,Tannu Suwal,Salma Al-Karmi,Mei Lu,Ben Ho,Maryam Fouladi,Sarah Leary,Jean M. Mulcahy Levy,Alvaro Lassaletta,Eloy Rivas,Alyssa Reddy,G. Yancey Gillespie,Nalin Gupta,Michal Yalon-Oren,Laura Amariglio,Hideo Nakamura,Kuo-Sheng Wu,Tai-Tong Wong,Young-Shin Ra,Milena La Spina,Policlinico Vittorio Emanuele,Luca Massimi,Anna Maria Buccoliero,Jordan R. Hansford,Richard G. Grundy,Dariusz Adamek,Jason Fangusaro,David Scharnhorst,Donna Johnston,Lucie Lafay-Cousin,Sandra Camelo-Piragua,Nabil Kabbara,Amar Gajjar,Mahjouba Boutarbouch,Maria Joao Gil da Costa,Derek Hanson,Paul Wood,Maysa Al-Hussaini,Nisreen Amayiri,Yin Wang,Daniel Catchpoole,Jean Michaud,Anne E. Bendel,Benjamin Ellezam,Nicholas Gerber,Ashley Plant,Rubens Jeffery,Christopher Dunham,Christopher Moertel,Andrew Walter,David Ziegler,Andrew Dodgshun,Nicholas Gottardo,Ahmet Demir,Ramya Ramanujachar,Eric Raabe,Shago Mary,Peter Dirks,Michael Taylor,Hwang Eugene,Holly Lindsey,Tarik Tihan,Jorgensen Mette,Christine Dahl,Sharon Low,Amy Smith,Lili-Naz Hazrati,Jesse Kresak,Somers Gino,Enrica Tan,Andres Morales,Vicente Santa-Maria,Cynthia Hawkins,Ute Bartels,Derek Stephens,Sumihito Nobusawa,Christelle Dufour,Franck Bourdeaut,Nicolas Andre,Eric Bouffet,Annie Huang
DOI: https://doi.org/10.1093/neuonc/noaa222.225
2020-01-01
Neuro-Oncology
Abstract:Abstract ETMR, an aggressive disease characterised by C19MC alterations, were previously categorised as various histologic diagnoses. The clinical spectrum and impact of conventional multi-modal therapy on this new WHO diagnostic category remains poorly understood as a majority of ~200 cases reported to date lack molecular confirmation. We undertook comprehensive clinico-pathologic studies of a large molecularly confirmed cohort to improve disease recognition and treatment approaches. Amongst 623 CNS-PNETs patients enrolled in the RBTC registry, 159 primary ETMRs were confirmed based on a combination of FISH (125), methylation analysis (88), SNP and RNAseq (32) analyses; 91% had C19MC amplification/gains/fusions, 9% lacked C19MC alterations but had global methylation features of ETMR NOS. ETMRs arose in young patients (median age 26 months) predominantly as localized disease (M0-72%, M2-3 -18%) at multiple locations including cerebrum (60%) cerebellum (18%), midline structures (6%); notably 10% were brainstem primaries mimicking DIPG. Uni-and multivariate analyses of clinical and treatment details of curative regimens available for 110 patients identified metastatic disease (p=0.002), brainstem locations(p=0.005), extent of surgery, receipt of multi-modal therapy including high dose chemotherapy and radiation (P<0.001) as significant treatment prognosticators, while C19MC status, age and gender were non-significant risk factors. Analyses of events in all patients showed respective EFS at 3 and 12 months of 84%(95%CI:77–91) and 37%(95%CI:20–41) and 4yr OS of 27%(95%CI:18–37) indicating despite intensified therapies ETMR is a rapidly progressive and fatal disease. Our comprehensive data on the largest cohort of molecularly-confirmed ETMRs provides a critical framework to guide current clinical management and development of clinical trials.